Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800339 | 0.88 | MAPT (0.41) | HDAC6MAPK1MTORCYP1A2MAPT | |
| SCHEMBL110183 | 0.83 | ATR (0.46) | ZAP70HDAC6ERN1MTORPDE10A | |
| SCHEMBL15976011 | 0.82 | KMT2A (0.42) | MTORMAPTHPGD | |
| SCHEMBL15976020 | 0.81 | ALDH1A1 (0.45) | MAPK1MAPTHPGD | |
| SCHEMBL15800327 | 0.78 | KMT2A (0.47) | ERN1MTORATRHPGD | |
| SCHEMBL15976016 | 0.76 | MAPT (0.43) | MAPTHPGD | |
| SCHEMBL15976000 | 0.76 | TACR3 (0.41) | MAPTHPGD | |
| SCHEMBL15800345 | 0.74 | KDR (0.37) | MAPK1MAPTHPGD | |
| SCHEMBL15976014 | 0.74 | ALDH1A1 (0.38) | ERN1CYP1A2MAPTCYP2C19HPGD | |
| SCHEMBL15800338 | 0.74 | MAPT (0.41) | HDAC6MAPK1MTORCYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | ZAP70 106/4885HDAC6 738/4885ERN1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.